TY - JOUR
T1 - Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors
AU - Grout, John A.
AU - Sirven, Philemon
AU - Leader, Andrew M.
AU - Maskey, Shrisha
AU - Hector, Eglantine
AU - Puisieux, Isabelle
AU - Steffan, Fiona
AU - Cheng, Evan
AU - Tung, Navpreet
AU - Maurin, Mathieu
AU - Vaineau, Romain
AU - Karpf, Lea
AU - Plaud, Martin
AU - Begue, Anne Laure
AU - Ganesh, Koushik
AU - Mesple, Jérémy
AU - Casanova-Acebes, Maria
AU - Tabachnikova, Alexandra
AU - Keerthivasan, Shilpa
AU - Lansky, Alona
AU - Le Berichel, Jessica
AU - Walker, Laura
AU - Rahman, Adeeb H.
AU - Gnjatic, Sacha
AU - Girard, Nicolas
AU - Lefevre, Marine
AU - Damotte, Diane
AU - Adam, Julien
AU - Martin, Jerome C.
AU - Wolf, Andrea
AU - Flores, Raja M.
AU - Beasley, Mary Beth
AU - Pradhan, Rachana
AU - Muller, Soren
AU - Marron, Thomas U.
AU - Turley, Shannon J.
AU - Merad, Miriam
AU - Kenigsberg, Ephraim
AU - Salmon, Hélène
N1 - Funding Information:
We thank the important contributions of patients who participated in this study. This project was supported by Genentech, Inc. and carried out in collaboration with the Fondation ARC pour la recherche sur le cancer. The computational work was supported by the Scientific Computing at the Icahn School of Medicine at Mount Sinai and the Office of Research Infrastructure of the NIH under award number S10OD026880. This manuscript was edited at Life Science Editors, and the cartoon illustrations were created using BioRender.com. We thank the Mount Sinai Flow Cytometry Core, the Human Immune Monitoring Center, and the Biorepository and Pathology Core for their support. We thank Sarah Lagha, Anne-Sophie Tedesco, Agathe Seguin-Givelet, and Isabelle Sauret for their contribution to obtaining and studying additional FFPE NSCLC samples from Institut Mutualiste Montsouris. We thank Eliane Piaggio, Ana-Maria Lennon-Duménil, and Olivier Lantz for carefully reading and commenting on the manuscript.
Funding Information:
We thank the important contributions of patients who participated in this study. This project was supported by Genentech, Inc. and carried out in collaboration with the Fondation ARC pour la recherche sur le cancer. The computational work was supported by the Scientific Computing at the Icahn School of Medicine at Mount Sinai and the Office of Research Infrastructure of the NIH under award number S10OD026880. This manuscript was edited at Life Science Editors, and the cartoon illustrations were created using BioRender.com. We thank the Mount Sinai Flow Cytometry Core, the Human Immune Monitoring Center, and the Biorepository and Pathology Core for their support. We thank Sarah Lagha, Anne-Sophie Tedesco, Agathe Seguin-Givelet, and Isabelle Sauret for their contribution to obtaining and studying additional FFPE NSCLC samples from Institut Mutualiste Montsouris. We thank Eliane Piaggio, Ana-Maria Lennon-Duménil, and Olivier Lantz for carefully reading and commenting on the manuscript. The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.
Publisher Copyright:
© 2022 American Association for Cancer Research.
PY - 2022/11/1
Y1 - 2022/11/1
N2 - It is currently accepted that cancer-associated fibroblasts (CAF) participate in T-cell exclusion from tumor nests. To unbiasedly test this, we used single-cell RNA sequencing coupled with multiplex imaging on a large cohort of lung tumors. We identified four main CAF populations, two of which are associated with T-cell exclusion: (i) MYH11+αSMA+ CAF, which are present in early-stage tumors and form a single cell layer lining cancer aggregates, and (ii) FAP+αSMA+ CAF, which appear in more advanced tumors and organize in patches within the stroma or in multiple layers around tumor nests. Both populations orchestrate a particular structural tissue organization through dense and aligned fiber deposition compared with T cell–permissive CAF. Yet they produce distinct matrix molecules, including collagen IV (MYH11+αSMA+ CAF) and collagen XI/XII (FAP+αSMA+ CAF). Hereby, we uncovered unique molecular programs of CAF driving T-cell marginalization, whose targeting should increase immunotherapy efficacy in patients bearing T cell–excluded tumors. SIGNIFICANCE: The cellular and molecular programs driving T-cell marginalization in solid tumors remain unclear. Here, we describe two CAF populations associated with T-cell exclusion in human lung tumors. We demonstrate the importance of pairing molecular and spatial analysis of the tumor micro-environment, a prerequisite to developing new strategies targeting T cell–excluding CAF.
AB - It is currently accepted that cancer-associated fibroblasts (CAF) participate in T-cell exclusion from tumor nests. To unbiasedly test this, we used single-cell RNA sequencing coupled with multiplex imaging on a large cohort of lung tumors. We identified four main CAF populations, two of which are associated with T-cell exclusion: (i) MYH11+αSMA+ CAF, which are present in early-stage tumors and form a single cell layer lining cancer aggregates, and (ii) FAP+αSMA+ CAF, which appear in more advanced tumors and organize in patches within the stroma or in multiple layers around tumor nests. Both populations orchestrate a particular structural tissue organization through dense and aligned fiber deposition compared with T cell–permissive CAF. Yet they produce distinct matrix molecules, including collagen IV (MYH11+αSMA+ CAF) and collagen XI/XII (FAP+αSMA+ CAF). Hereby, we uncovered unique molecular programs of CAF driving T-cell marginalization, whose targeting should increase immunotherapy efficacy in patients bearing T cell–excluded tumors. SIGNIFICANCE: The cellular and molecular programs driving T-cell marginalization in solid tumors remain unclear. Here, we describe two CAF populations associated with T-cell exclusion in human lung tumors. We demonstrate the importance of pairing molecular and spatial analysis of the tumor micro-environment, a prerequisite to developing new strategies targeting T cell–excluding CAF.
UR - http://www.scopus.com/inward/record.url?scp=85141209983&partnerID=8YFLogxK
U2 - 10.1158/2159-8290.CD-21-1714
DO - 10.1158/2159-8290.CD-21-1714
M3 - Article
C2 - 36027053
AN - SCOPUS:85141209983
SN - 2159-8274
VL - 12
SP - 2606
EP - 2625
JO - Cancer Discovery
JF - Cancer Discovery
IS - 11
ER -